Quantitative measurement of lysophosphatidylcholine derivatives of very long-chain fatty acids (C22:0, C24:0, C26:0) from dried blood spot by LC-MS/MS for screening of X-linked adrenoleukodystrophy and other peroxisomal disorders.
C26:0-LPC, C24:0-LPC, C22:0-LPC + ratios
3–5 working days
This method screens for peroxisomal disorders by quantifying lysophosphatidylcholine derivatives of very long-chain fatty acids (LPC-VLCFA) from a dried blood spot. The primary indication is screening for X-linked adrenoleukodystrophy (X-ALD), affecting approximately 1 in 16,800 to 1 in 20,000 births — though the incidence may be higher with expanded newborn screening programmes.
The test detects elevated VLCFA levels that indicate impaired peroxisomal beta-oxidation, the enzymatic pathway responsible for breaking down very long-chain fatty acids. Beyond X-ALD, this method also screens for:
Early detection is critical because hematopoietic stem cell transplantation (HSCT) is currently the only accepted therapy capable of halting disease progression in the cerebral form of X-ALD when performed before symptom onset or early in the disease course.
X-linked adrenoleukodystrophy is an inherited metabolic disorder caused by mutations in the ABCD1 gene, which encodes a peroxisomal transporter protein essential for import of very long-chain fatty acids (VLCFAs) into peroxisomes. Without functional ABCD1, VLCFAs cannot be properly oxidised, leading to pathological accumulation in plasma, red blood cells, and tissues.
Estimated incidence of X-ALD at birth, making it a critical target for expanded newborn screening
HSCT can halt disease progression in the cerebral form when performed early, before neurological damage
Female carriers of ABCD1 mutations identified through LPC-VLCFA screening enable family counselling and reproductive planning
The pathophysiology involves accumulation of saturated VLCFAs (particularly C26:0, C24:0, and C22:0) which are incorporated into complex lipids including lysophosphatidylcholines. In X-ALD, the VLCFA content of lipids increases dramatically, resulting in abnormal membrane composition and neuroinflammatory activation. The peroxisomal dysfunction leads to progressive demyelination, particularly in the cerebral white matter, adrenal cortex dysfunction, and peripheral nerve involvement.
X-ALD presents with multiple phenotypes: childhood cerebral ALD (CCALD) manifests between 4 and 10 years with rapid progression to disability; adrenomyeloneuropathy (AMN) typically appears in the second to third decade with slower progression; and the Addison-only phenotype presents with isolated adrenal insufficiency without neurological involvement. Female carriers may remain asymptomatic or develop a milder neurological syndrome.
LPC-VLCFA measurement in dried blood spots has emerged as the superior screening biomarker compared to traditional plasma VLCFA measurement. LPC derivatives are more stable in DBS, require minimal sample volume, and have demonstrated higher diagnostic sensitivity and specificity in newborn screening programmes worldwide.
Lysophosphatidylcholine derivatives of very long-chain fatty acids are extracted from dried blood spots and quantified by high-resolution LC-MS/MS using stable isotope-labelled internal standards. The method simultaneously measures C26:0-LPC, C24:0-LPC, and C22:0-LPC, and typically reports the diagnostic ratio of C26:0-LPC to C22:0-LPC, which exhibits excellent separation between healthy individuals and affected patients.
The superiority of LPC-VLCFA measurement over traditional plasma VLCFA quantification stems from several factors: LPC derivatives demonstrate greater stability in the DBS matrix at ambient temperature, requiring no special storage or rapid processing; the measurement is more sensitive and specific for detecting disease; and DBS collection is ideal for population screening, including remote and resource-limited settings.
Dried blood spot collection from a heel prick in newborns is the standard approach for population screening. The sample can be collected at home or in clinic, transported by standard mail, and stored at room temperature for extended periods without loss of analyte stability — making LPC-VLCFA testing highly suitable for universal newborn screening programmes.
From enquiry to results in a few simple steps — no clinic visit required.
This test is available to healthcare professionals, wellness brands, clinics, and research institutions worldwide. We currently serve partners in:
Whether you need testing services for your patients, white-label kits for your brand, or method transfer to your own laboratory — get in touch to discuss how we can work together.
X-ALD is an inherited metabolic disorder caused by mutations in the ABCD1 gene, leading to accumulation of very long-chain fatty acids (VLCFAs) in plasma, tissues, and the central nervous system. It affects approximately 1 in 17,000 births. Without early detection, the cerebral form causes devastating and irreversible neurological decline, including progressive demyelination and loss of motor and cognitive function.
The test measures lysophosphatidylcholine (LPC) derivatives of very long-chain fatty acids — specifically C26:0-LPC, C24:0-LPC, and C22:0-LPC — from a dried blood spot by LC-MS/MS. Elevated ratios, particularly C26:0-LPC to C22:0-LPC, indicate impaired peroxisomal beta-oxidation and are highly diagnostic for X-ALD and related peroxisomal disorders.
A simple finger-prick or heel prick is used to collect a few drops of blood onto a dried blood spot (DBS) card. The LPC-VLCFA analytes are highly stable in the DBS matrix at room temperature, making this collection method ideal for newborn screening and remote sampling.
Results are typically delivered within 3 to 5 working days from the time your sample arrives at our laboratory. The analysis is performed by LC-MS/MS, providing accurate quantification of VLCFA-LPC species and diagnostic ratios.
Yes, LPC-VLCFA testing is increasingly included in newborn screening programmes worldwide. Early detection enables monitoring and timely haematopoietic stem cell transplantation (HSCT) before symptom onset — currently the only accepted therapy capable of halting disease progression in the cerebral form of X-ALD.
Masdiag's LPC-VLCFA screening test is available worldwide through our partner network. We currently serve healthcare professionals, newborn screening programmes, and clinics in Europe, the United Kingdom, Asia, Australia, New Zealand, and the United States. Contact us to discuss testing services or method transfer.
Whether you need testing services, method transfer, or white-label kit development — we'd love to hear from you.